March 20, 2024 – Talk Bio

FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients

1 year ago talkbio0Tagged 12.5 mg, Approved, aprocitentan, aspects of adverse effects, Availability of, Clinical Trials, Combined Modality Therapy, Edema, Endothelin receptor antagonist, Idorsia, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, Liquid substance, Precision - temporal, Recommended dosage, Resistant hypertensive disorder, Retention (Psychology), Second Half of 2024, Tryvio, Uncontrolled hypertension, United States Food and Drug Administration

FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects

Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies

1 year ago talkbio0Tagged Ataxia Telangiectasia Mutated Proteins, Catalio Capital Management, cellular targeting, CEO, CLASRP gene, engagers, financing characteristics, HLA Molecule Profiling, Holdings, Personalized Off-the-Shelf Therapies, Robert Ross, T-Lymphocyte, Third Rock

Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross

Lonza Acquires Roche’s Massive Biologics Production Facility in Vacaville, California for $1.2 Billion

1 year ago talkbio0Tagged Biologics Manufacturing Site, California, Capacity, CDMOs, Contract Development, genentech, Global Biologics Market, Growth, Large-Scale Commercial Mammalian Products, Lonza, manufacturing organizations, Roche (company), utilization qualifier, Vacaville

Lonza, Roche, Genentech, Biologics Manufacturing Site, Vacaville/ California, $1.2 Billion Deal, Large-Scale Commercial Mammalian Products, Expansion Plans ($561 Million), Capacity Utilization, Contract Development and Manufacturing Organizations (CDMOs), Global Biologics Market Growth